乾癬治療薬の世界市場予測2016-2026...市場調査レポートについてご紹介

【英文タイトル】Psoriasis Drugs Market Forecasts 2016-2026

▼当市場調査レポートの詳細内容確認、お問い合わせ及びご購入申込は下記ページでお願いします。▼マーケットレポート

【レポートの概要(一部)】

1. Report Overview
1.1 Psoriasis Overview
1.2 Psoriasis Market Segmentation
1.3 Why You Should Read this Report
1.4 How this Report Delivers
1.5 Main Questions Answered by this Report
1.6 Who is this Report for?
1.7 Research and Analysis Methods
1.8 Frequently Asked Questions (FAQ)
1.9 Some Associated Reports
1.10 About Visiongain

2. Introduction to Psoriasis
2.1 Understanding Skin
2.2 What is Psoriasis?
2.3 What Causes Psoriasis?
2.3.1 Genetic Factors
2.3.2 Environmental Factors
2.4 World Prevalence of Psoriasis
2.5 How is Psoriasis Treated?
2.5.1 Biologic Drugs
2.5.2 Small Molecule Systemic Drugs
2.5.3 Topical Therapies
2.6 Classification of Severity

3. The World Drug Market for Psoriasis 2016-2026
3.1 The World Drug Market for Psoriasis in 2015: Biologic Drugs Dominate In Terms of Revenue
3.2 The World Drug Market for Psoriasis: Overarching Revenue Forecast 2016-2026
3.3 The World Drug Market for Psoriasis by Therapeutic Subclass: Comparison of Revenues and Market Shares to 2026
3.4 The World Drug Market for Psoriasis by Therapeutic Subclass: Grouped Revenue Forecast 2016-2026
3.5 Biologic Drugs for Psoriasis: Blockbuster Revenue for 2015
3.5.1 Biologic Drugs for Psoriasis: Revenue Forecast, 2016-2026
3.6 Topical Therapies for Psoriasis: The Most Commonly Prescribed Treatments
3.6.1 Topical Therapies for Psoriasis: Revenue Forecast, 2016-2026
3.7 Small Molecule Systemic Treatments for Psoriasis: A Subclass with Promise
3.7.1 Small Molecule Systemic Treatments for Psoriasis: Revenue Forecast, 2016-2026

4. Leading Drugs of the Psoriasis Treatment Market, 2016-2026
4.1 The Leading Drugs on the Market in 2015: Three Drugs Achieved Blockbuster Success
4.2 Leading Psoriasis Drugs: Comparison of Revenues and Market Shares, 2021 and 2026
4.3 Leading Psoriasis Drugs: Grouped Forecasts 2016-2026
4.4 Humira: Blockbuster Revenue from Psoriasis Indications 2015
4.4.1 Threat from Biosimilars
4.4.2 Humira: Revenue Forecast 2016-2026
4.5 Stelara: A Strong Performer in Psoriasis
4.5.1 Competition for Stelara in the Pipeline
4.5.2 Stelara: Revenue Forecast, 2016-2026
4.6 Enbrel: Facing Competition from Biosimilars
4.6.1 Sales of Enbrel in 2015
4.6.2 Patent Expiries
4.6.3 Threat from Biosimilars
4.6.4 Enbrel: Revenue Forecast, 2016-2026
4.7 Remicade: Facing a Declining Market Share
4.7.1 Threat from Biosimilars
4.7.1.1 Inflectra/Remsima: First Infliximab Biosimilar
4.7.1.2 Flixabi: Biosimilar from Samsung Bioepis
4.7.2 Remicade: Revenue Forecast, 2016-2026
4.8 Otezla: A Promising New Therapy
4.8.1 Otezla: Revenue Forecast, 2016-2026
4.9 Daivobet: A Widely Prescribed Topical Treatment
4.9.1 Daivobet: Revenue Forecast, 2016-2026
4.10 Soriatane: Generic Competition Eroding Sales
4.10.1 Soriatane: Revenue Forecast, 2016-2026
4.11 Cosentyx: First IL-17 Inhibitor on the Market
4.11.1 Cosentyx: Revenue Forecast, 2016-2026
4.12 Simponi: Growth Limited by its Indications
4.12.1 Simponi: Revenue Forecast, 2016-2026
4.13 Tazorac: Facing Competition from Generics
4.13.1 Tazorac: Revenue Forecast, 2016-2026
4.14 Promising Compounds in the Pipeline
4.14.1 Taltz: Second IL-17 Inhibitor to Reach the Market
4.14.1.1 Taltz: Revenue Forecast 2016-2026
4.14.2 Tildrakizumab: Positive Phase III Data
4.14.2.1 Tildrakizumab: Revenue Forecast 2016-2026
4.14.3 Guselkumab: Promising IL-23 Inhibitor
4.14.3.1 Guselkumab: Revenue Forecast 2016-2026

5. Leading National Markets for Psoriasis Treatment, 2016-2026
5.1 The Leading National Markets in 2015: The US Dominates the Psoriasis Market
5.2 The Leading National Markets: Comparison of Revenues and Market Shares to 2026
5.3 The Leading National Markets: Grouped Revenue Forecasts 2016-2026
5.4 The US: Large Population and Large Financial Resources Mean There is a Large Market for Psoriasis Drugs
5.4.1 The US Psoriasis Drug Market: Revenue Forecast 2016-2026
5.5 The EU Psoriasis Drug Market: 2015-2026
5.5.1 The Psoriasis Drug Market in Germany: Revenue Forecast 2016-2026
5.5.2 The Psoriasis Drug Market in France: Revenue Forecast 2016-2026
5.5.3 The Psoriasis Drug Market in the UK: Revenue Forecast 2015-2026
5.5.4 The Psoriasis Drug Market in Italy: Revenue Forecast 2015-2026
5.5.5 The Psoriasis Drug Market in Spain: Revenue Forecast 2015-2026
5.6 Japan: The Second Largest National Market in 2015
5.6.1 The Psoriasis Drug Market in Japan: Revenue Forecast 2015-2026
5.7 China: The Psoriasis Drug Market is Growing Steadily
5.7.1 The Psoriasis Drug Market in China: Revenue Forecast 2015-2026
5.8 India: Low Healthcare Spending Limits Sales
5.8.1 The Psoriasis Drug Market in India: Revenue Forecast 2015-2026
5.9 Russia: Experiencing Troubled Times
5.9.1 The Psoriasis Drug Market in Russia: Revenue Forecast 2015-2026
5.10 Brazil: Encouraging Domestic Manufacturers
5.10.1 The Psoriasis Drug Market in Brazil: Revenue Forecast 2015-2026

6. Psoriasis R&D Pipeline, 2016
6.1 Biologics
6.1.1 Brodalumab: Less Promising Than Expected
6.1.2 BI 655066: First IL-23 to Reach the Market?
6.1.3 Cimzia: Potential Licence Expansion to Psoriasis
6.1.4 Orencia: Efficacy in Psoriasis and Psoriatic Arthritis?
6.1.5 ABT-122: A Dual Action Molecule
6.1.6 Namilumab: Novel Mechanism of Action
6.1.7 Biosimilars: The Growing Threat to Biologics
6.2 Small Molecule Systemic Treatments
6.2.1 Xeljanz: Approval in the Balance
6.2.2 CF-101: Efficacy in Question
6.2.3 Baricitinib: Janus Kinase Inhibitor
6.2.4 JNJ 168: Histamine Receptor Antagonist
6.2.5 Prurisol: Will its Phase II Study Succeed?
6.3 Topical Molecules
6.3.1 IDP-118 Lotion: Combines Steroid and Retinoid
6.3.2 M518101 Ointment: Phosphodiesterase Inhibitor
6.3.3 122-0551 Foam: Steroid-Based Product

7. Leading Companies in the Psoriasis Drug Market, 2016
7.1 The Leading Companies in the Market
7.2 Johnson & Johnson: Top Performer in Psoriasis
7.3 AbbVie: Highly Reliant on Humira
7.4 Amgen: Actively Developing Biosimilars
7.5 Pfizer: Hospira Acquisition Boosts Biosimilar Portfolio
7.6 LEO Pharma: Specialises in Dermatology
7.7 Celgene: Sales Boosted by Otezla
7.8 Novartis: Cosentyx Performing Well
7.9 GSK: Looking to Expand Their Immunology Portfolio
7.10 Merck: A Limited Share of the Market

8. Qualitative Analysis of the Psoriasis Market, 2016-2026
8.1 Strengths and Weaknesses of the Psoriasis Drug Market, 2016-2026
8.1.1 Strengths of High Patient Demand, Active Research and High Revenue Potential
8.1.2 Weaknesses from Shortcomings of Current Treatments and Patent Expiries
8.2 The Opportunities and Threats Facing the Psoriasis Drug Market, 2016-2026
8.2.1 Opportunities of Patient Demand for Improved Treatments
8.2.2 Threats from Financial Restrictions and Market Saturation
8.3 Social, Technological, Economic and Political Factors Influencing the Psoriasis Drug Market (STEP analysis), 2016-2026
8.3.1 Social Factors Influencing the Market
8.3.2 Technological Factors Affecting the Psoriasis Drug Market
8.3.3 Economic Impact of Psoriasis Treatment
8.3.4 Political Considerations Influencing Drug Approval
8.3.4.1 Biosimilar Approval in Developed Countries
8.3.4.2 Biosimilar Approval in Developing Countries

9. Conclusions
9.1 The World Market Value for Psoriasis Drugs, 2016-2026
9.2 Leading Drugs of the Psoriasis Treatment Market, 2016-2026
9.3 Leading National Markets for Psoriasis Drugs, 2016-2026
9.4 Leading Companies in the Market
9.5 Trends in the Psoriasis Drugs Market


【レポート販売概要】

■ タイトル:乾癬治療薬の世界市場予測2016-2026
■ 英文:Psoriasis Drugs Market Forecasts 2016-2026
■ 発行日:2016年6月
■ 調査会社:visiongain
■ 商品コード:VGAIN60710
■ 調査対象地域:グローバル
※当サイトは世界の市場調査レポート紹介サイトです。市場規模、市場動向、市場予測など、多様な分析データを含むグローバル調査レポートをご案内致します。日本国内を含むアジア太平洋、中国、ヨーロッパ、アメリカ、北米、中南米、中東、アフリカ地域などにおける、製品、サービス、技術、企業(メーカー、ベンダー)、市場シェア、市場環境など多様な項目に対応致します。当サイトでご紹介するレポートは「市場調査レポート販売サイトのMarketReport.jp」でお問い合わせ及びご購入可能です。